NEW YORK (GenomeWeb) – Biotech firm Sygnis said today that it is acquiring UK-based proteomics reagents company Expedeon.

The deal broadens Sygnis' genomics-focused product portfolio to include protein research and gives it access to Expedeon's sales forces in the US and Europe, the company said.

Sygnis will purchase Expedeon for €1.7 million ($1.9 million) in cash and an additional amount of stock, financing the transaction by issuing up to 20.5 million new shares, which will raise up to €20.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.